MSG Team's other articles

9927 Information System for Knowledge Management

Introduction Knowledge is very important for survival of organization. Historically, employees have gathered knowledge through trial-and-error method or by working as an apprentice under a tenured knowledgeable employee. Management guru Peter Drucker forwarded a concept that knowledge is as valuable as a company’s various asset like plant, machinery, etc. Importance of Knowledge Management Knowledge provides […]

12844 Components of Commercial Value Chain

Introduction The concept of the value chain was introduced by Michael Porter. The concept helps categories’ activities undertaken by enterprise to deliver a successful product to a customer. The concept since its introduction in 1980s has become a forefront in developing strategies around customer delight and commercial success. The value chain is series of activities […]

12399 Measuring Process through Balanced Scorecards

The Harvard Business Review in 1992 took the business world by storm when Kaplan and Norton introduced the idea of balanced scorecard. They argued that even though strategic management was being pursued as an organization wide goal in companies worldwide, in effect they were doing a post-mortem of the business situation at hand. Measurement was […]

9575 How Central Bankers and Policymakers are Losing Control of the Global Economy

The US Fed and Tapering of Quantitative Easing (QE) The recent announcement that the United States Federal Reserve was thinking of tapering the Quantitative Easing program or QE immediately spooked the stock markets, which went into free fall. Mind you, this was not the actual tapering off the program but just a line of thought. […]

10772 What is Productivity and Why it is Important to Corporates, Nations, and Professionals?

What is Productivity and Why it is so Important? We often hear the term Productivity, bandied about in economics and management textbooks and the popular press. Indeed, not a day goes by without this term popping up in myriad contexts. Further, when experts talk about falling or rising productivity, they stress its importance to everything […]

Search with tags

  • No tags available.

The e-pharmacy sector in India has been witnessing a lot of startup activity. More than 200 start-ups have sprung up in this space, and some of them have gained considerable resources. For example, 1mg has raised more than $50 million in seed funding from American private equity firms. Medlife, which is a similar start-up has raised over $30 million in order to expand its network and last mile connectivity. PharmEasy, which is a relatively new entrant, has also been able to obtain $17 million in venture funding. The e-pharma start-up space appears to be really heating up. Experts are predicting that some mergers and acquisitions activity might take place to reduce the increasing number of startups that are entering this line of business.

In this article, we will have a closer look at some of the fundamental issues that are affecting the e-commerce industry.

Legality Issues: The pharmacy industry in India, i.e., the sale of medicines to end consumers has been estimated to be worth more than 1.2 lakh crore rupees. The e-pharma industry is a very small segment which has started flourishing now. The combined revenue of these online startups is less than 1000 crore per annum. Hence, e-pharma is at a very nascent stage because it does not even constitute even 1% of the total pharma market.

This is largely because of the legality issues facing these companies. India has a complex regulatory environment for the sale of medicines. Consumers are not sure whether these startup companies are able to comply with these regulatory norms. Also, counterfeit medicines are very common in India. Due to the deep discounts being offered by these e-pharma companies many consumers suspect that they might be selling counterfeit medicines. The pharmacy companies have started registering all suppliers and manufacturers. This is being done to eradicate the suspicion that e-pharma firms are selling counterfeit goods.

Slow Growth Rate

The government is skeptical about e-pharma firms. This is the reason they keep a close watch on these firms. It is widely believed that giving a free hand to e-pharma firms might lead to drug abuse. This is because these firms are likely to sell habit-forming drugs without the correct prescription.

This is the reason why e-pharma firms are very careful about the drugs that they sell. About 45% of the orders placed by the customers are rejected due to the lack of a valid prescription. This is not the case offline where the same consumers are able to buy these drugs. Since e-pharma companies reject orders on such a large scale, their growth rate is quite slow. However, it is better to grow at a slow rate than to jeopardize the existence of the entire industry.

Regulatory Hurdles

E-pharma startups want to expand their business all over India. This will give them the necessary scale wherein they can negotiate with the suppliers to get better discounts. However, the rules and laws put in place by the government are very strict.

At the present moment, e-pharma companies must obtain a separate license for every state that they want to sell medicines in. Also, they are required to have a physical presence in all states. This leads to increased costs for online retailers whose business model is dependent upon avoiding physical presence to keep costs low.

With so many rules in place, e-pharma companies find it difficult to build an efficient supply chain which can bring down the cost of medicines and therefore add value to customers. Inter-state supply chains are a distant dream as of now. However, since the market has so much potential, a lot of these startups have been lobbying the central government. They want to be able to operate with a single license that allows them to distribute medicines all over India. Also, they want to able to build interstate supply lines.

Hurdles in Integration

E-pharma companies have tried venturing into related businesses like diagnostics and lab testing. However, there are regulatory hurdles here as well. There are several laws which make it difficult for e-pharma companies to have such vertical or horizontal integration.

These restrictions are likely to have a severe impact on the valuation of these firms. Investors are well aware that they do not have any wriggle room. Their operations are being straitjacketed. They are only allowed to sell some medicines to a certain group of customers. If they try to expand their customer group or the medicines they are selling, they face regulatory hurdles. Similarly, if they try to enter a new line of business, they face hurdles again. This lack of flexibility translates into lower valuations.

A lot of these laws are actually counterproductive and should be repealed. However, there is a very strong offline pharmacist lobby. Since their turnover is much higher than then online pharmacies, they can lobby the government just to let things be the way they currently are.

Multiple Laws

The problem with e-pharma companies is that they have to comply with multiple laws. There is the IT Act as well as the Drugs and Cosmetics Act. Sometimes the provisions of these laws contradict each other. This creates ambiguity as well as more litigation costs for the e-pharma firms.

The bottom line is that e-pharma firms have a lot of potential in India. However, they face opponents who are well connected and who have deep pockets. Also, the regulatory mechanism is not in their favor.

Article Written by

MSG Team

An insightful writer passionate about sharing expertise, trends, and tips, dedicated to inspiring and informing readers through engaging and thoughtful content.

Leave a reply

Your email address will not be published. Required fields are marked *

Related Articles